Touchlight
Hampton, United Kingdom
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (9)
○ EMA GMP
○ MHRA GMP
Quick Facts: Touchlight
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Hampton, United Kingdom
- Modalities
- Circular ssDNA (MegaBulb/mbDNA), Linear covalently-closed DNA (dbDNA), Plasmid DNA (cell-free), mRNA template DNA, Gene editing HDR templates
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Touchlight
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCircular ssDNA (MegaBulb/mbDNA), Linear covalently-closed DNA (dbDNA), Plasmid DNA (cell-free), mRNA template DNA, Gene editing HDR templates
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press9 articles
Broad modality coverage (5 modalities)
Recent News 9 articles
GSK inks deal with CDMO Touchlight for access to its ‘doggybone DNA’ tech - Fierce Pharma
Touchlight Announces First FDA Clearance of an IND Utilising Doggybone DNA - Business Wire
After Touchlight's Pfizer pact, CDMO Curia gets its hands on firm's 'doggybone' DNA platform - Fierce Pharma
Touchlight’s Hampton, UK Facility Receives GMP Certification from MHRA - Contract Pharma
Lonza, Touchlight partner on 'doggybone DNA' development - Fierce Pharma
DNA maker Touchlight adds Lonza manufacturing vet as it swings at COVID-19 vaccine, cell and gene therapy markets - Fierce Pharma
Touchlight Highlights Strategic Shift From Plasmid to Cell‑Free DNA in Gene Therapy - TipRanks
Production of lentiviral vectors using novel, enzymatically produced, linear DNA - Nature
Touchlight boosts DNA manufacturing capacity with latest expansion - Pharmaceutical Technology
Frequently Asked Questions About Touchlight
What is Touchlight's CDMO Signal Score?
Touchlight has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Touchlight for a manufacturing program?
Use the free AI matchmaker to compare Touchlight against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: